GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (CHIX:ZEALc) » Definitions » 3-Year EPS without NRI Growth Rate

Zealand Pharma A/S (CHIX:ZEALC) 3-Year EPS without NRI Growth Rate : 16.80% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma A/S 3-Year EPS without NRI Growth Rate?

Zealand Pharma A/S's EPS without NRI for the three months ended in Dec. 2023 was kr-2.22.

During the past 3 years, the average EPS without NRI Growth Rate was 16.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Zealand Pharma A/S was 16.80% per year. The lowest was -59.50% per year. And the median was -15.85% per year.


Competitive Comparison of Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate falls into.



Zealand Pharma A/S 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Zealand Pharma A/S  (CHIX:ZEALc) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Zealand Pharma A/S 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (CHIX:ZEALC) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (CHIX:ZEALC) Headlines

No Headlines